21 Aug. 64 – Dr. Witoon Danwiboon, Director of the Government Pharmaceutical Organization, said that the plant (Vaccination) biomaterial, Thap Kwang Sub-district, Kaeng Khoi District, Saraburi Province of the Government Pharmaceutical Organization The World Health Organization (WHO) compliant facility has entered the Facility of the Year Awards 2021 (FOYA) contest of the International Society for Pharmaceutical Engineering (ISPE), an international member organization that operates in Pharmaceutical Technology and Engineering. Over 18,000 cases located in more than 90 countries by a panel of judges who are outstanding industry leaders. and has a lot of world-class experience Considered that the biomaterial factory (vaccination) plant of the district office received awards in the category of Social Impact from 6 categories, all the awards that are presented this year, namely, Facility Integration, Operational Excellence, Project Execution, Process Intelligence and Innovation, Social Impact and Special Recognition Award for Operational Agility: COVID-19 Impact
“The vaccine factory has received a world-class award this time. It is another important encouragement for practitioners to strive to develop quality vaccine production. Build stability and sustainability in vaccines for Thailand. both in normal situations and situations with outbreaks of disease The official award ceremony will be held at the ISPE Annual Meeting and Expo from October 31 – November 2, 2021 in Boston. United States of America”
Mr. Kittisak Phuphiphatphon, Special Expert Pharmaceutical Organization Responsible for vaccines and biomaterial, said that the plant (vaccine) biomaterial of the organization that has won this world-class award. have outstanding works Innovation in the development and production of influenza vaccines Especially in this epidemic situation of COVID-19, the technology of vaccine production using hatching chicken eggs has already been developed with potential and readiness. for use in the production of the COVID-19 vaccine by the organization The source virus obtained from PATH under an agreement between PATH and the Icahn School of Medicine at Mount Sinai and the University of Texas at Austin was used to research and develop a COVID-19 vaccine. The Phase I human trial has now achieved immunization results at 14 days after two doses of vaccination, and a Phase 2 human trial has begun and will continue in Phase 3. It will begin industrial production after the vaccine has been registered by the Food and Drug Administration. It is expected that by 2022, it will apply for a recipe registration and start producing industrial vaccines for use. with a production capacity of 20-30 million doses per year.”
“Most importantly, this factory was built for social duty. Build sustainability in vaccines in Thailand Increasing access to vaccines both in the normal situation and preventing shortages of vaccines in the country from epidemic situations or when there are health crises in various countries. The factory is designed to be sustainable as a Green Factory. resource efficiency Reduce the emission of waste to the outside with the waste disposal system from the work process according to the specified standards reduce carbon emissions Install a solar rooftop power generation system in every building, which is friendly and reduces environmental impact.”
.
